JOINT FILING AGREEMENTJoint Filing Agreement • January 31st, 2022 • SOL Global Investments Corp. • Pharmaceutical preparations
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
EMPLOYMENT AGREEMENTEmployment Agreement • August 21st, 2017 • Scythian Biosciences Corp. • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated and effective as of the ____day of _____________ , 2017 (the “Effective Date”), is entered by and between Scythian Biosciences, Corp., a body corporate formed under the Business Corporations Act of Canada (the “Company”), with a registered office located at ______________________and Jonathan Gilbert (the “Executive”) having an address at 36 Sycamore Lane, Roslyn Heights, New York 11577. The Company and the Executive may hereinafter be referred to individually as a “Party” or collectively as the “Parties”.
UNDERWRITING AGREEMENTUnderwriting Agreement • February 13th, 2018 • Scythian Biosciences Corp. • Pharmaceutical preparations • Ontario
JOINT FILING AGREEMENTJoint Filing Agreement • May 3rd, 2021 • SOL Global Investments Corp. • Pharmaceutical preparations
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
SCYTHIAN BIOSCIENCES INC. - and – KITRINOR METALS INC. - and – Clarus SECURITIES Inc. - and – TSX TRUST COMPANy SUBSCRIPTION RECEIPT AGREEMENT Providing for the Issue of up to 35,000,000 Subscription Receipts at a Price of $0.40 per Subscription...Subscription Receipt Agreement • August 21st, 2017 • Scythian Biosciences Corp. • Ontario
NOW THEREFORE, THIS AGREEMENT WITNESSES that for good and valuable consideration mutually given and received, the receipt and sufficiency of which is hereby mutually acknowledged, it is hereby agreed and declared as follows:
JOINT FILING AGREEMENTJoint Filing Agreement • August 17th, 2021 • SOL Global Investments Corp. • Pharmaceutical preparations
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • August 21st, 2017 • Scythian Biosciences Corp. • Florida
THIS COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) is entered into as of the 25th day of July, 2016 (the “Effective Date”) by and between Scythian Biosciences Inc., having offices at Scythian Biosciences Inc. 101-1865 Dilworth Drive #737 Kelowna, BC V1Y 9Tl 250-864-2740 Canada (“Company”), and University of Miami, a not-for-profit corporation having an office at 1320 S. Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the “Institution”). Each of Company and Institution are sometimes referred to herein as a “Partv” or, jointly, as the “Parties.”
AMENDING AGREEMENTAmending Agreement • August 21st, 2017 • Scythian Biosciences Corp. • Ontario
THIS AMENDING AGREEMENT is made as of the ___ day of ________, 2017 between SCYTHIAN BIOSCIENCES INC., a corporation existing under the federal laws of Canada (the “Company”), KITRINOR METALS INC., a corporation existing under the laws of Ontario (“Kitrinor”), CLARUS SECURITIES INC., as lead agent in respect of the Offering (“Clarus” or the “Lead Agent”), HAYWOOD SECURITIES INC. and CANACCORD GENUITY CORP. (together with the Lead Agent, the “Agents”).
SUBSCRIPTION RECEIPT AGREEMENT SUPPLEMENTSubscription Receipt Agreement Supplement • August 21st, 2017 • Scythian Biosciences Corp. • Ontario
THIS AGREEMENT is made as of the ● day of June, 2017 between Scythian Biosciences Inc., a company incorporated under the federal laws of Canada (the “Company”), Kitrinor Metals Inc., a company incorporated under the laws of the Province of Ontario (“Kitrinor”), TSX Trust Company, a trust company continued under the laws of Canada (“TSXT”) and Clarus Securities Inc. (“Clarus”).
AGENCY AGREEMENTAgency Agreement • August 21st, 2017 • Scythian Biosciences Corp. • Ontario
Scythian Biosciences Inc. 100 King Street West, Suite 1600 Toronto, Ontario M5X 1G5 Kitrinor Metals Inc. 365 Bay Street, Suite 400 Toronto, Ontario M5H 2V1
CONSULTANT AGREEMENTConsultant Agreement • August 21st, 2017 • Scythian Biosciences Corp. • Ontario
THIS CONSULTANT AGREEMENT (the “Agreement”), dated and effective as of the _______ day of __________ 2017 (the “Commencement Date”), is entered by and between Scythian Biosciences Corp., a body corporate formed under the Business Corporations Act (Ontario) (the “Company”), with a registered office located at 1 First Canadian Place, 100 King Street West, Toronto, Ontario, M5X 1G5, Canada and ALOE Finance Inc. (“Consultant”) having an address at 366 Bay Street, Suite 200, Toronto, Ontario, M5H 4B2. The Company and Consultant may hereinafter be referred to individually as a “Party” or collectively as the “Parties”.
JOINT FILING AGREEMENTJoint Filing Agreement • September 10th, 2021 • SOL Global Investments Corp. • Pharmaceutical preparations
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.
AMENDMENT TO COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • October 18th, 2017 • Scythian Biosciences Corp. • Pharmaceutical preparations
This Amendment is hereby made on this 6th day of October 2017. The Parties hereto have previously entered into a COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) on July 25, 2016 between Scythian Biosciences Inc. which through amalgamation is now Scythian Biosciences Corp. (the “Company”), and University of Miami (the “Institution”). Each of the Company and Institution are sometimes referred to herein as a “Party” or, jointly, as the “Parties.”
Amendment No.1 to Collaborative Research AgreementCollaborative Research Agreement • August 21st, 2017 • Scythian Biosciences Corp.
THIS AMENDMENT TO the Collaborative Research Agreement (“Amendment”) is hereby made and entered into this 10th day of February 2017, by and between the University of Miami (“Institution”) and Scythian Biosciences, Inc. (“Company”).
Commercial LeaseCommercial Lease • August 21st, 2017 • Scythian Biosciences Corp. • British Columbia
SUBLEASESublease • August 21st, 2017 • Scythian Biosciences Corp. • British Columbia
NOW THEREFORE THIS SUBLEASE WITNESSETH that in consideration of the sum of TEN DOLLARS ($10.00) now paid by each of the parties to the other, the receipt and sufficiency of which is hereby respectively acknowledged, the parties hereto agree as follows:
